Prometheus Laboratories Inc announced that it has received New York State approval for PROMETHEUS IBS Diagnostic, the first and only blood test for irritable bowel syndrome (IBS). This novel test incorporates 10 biomarkers, two of which are proprietary, along with a proprietary algorithm to help physicians diagnose patients with IBS. “One out of five Americans has symptoms of IBS, however the majority go untreated due in part to current limitations in diagnostics,” said Henry Pan, M.D., Ph.D., Chief Scientific and Medical Officer of Prometheus. “PROMETHEUS IBS Diagnostic is a valuable tool that can help accelerate the diagnosis and treatment of IBS. We have worked diligently with the New York State Department of Health to ensure that this innovative test is broadly available to patients in need. In addition, we are pleased to report that a manuscript describing PROMETHEUS IBS Diagnostic has recently been accepted for publication in Alimentary Pharmacology & Therapeutics.” As with Prometheus’ entire portfolio of proprietary diagnostics, PROMETHEUS IBS Diagnostic testing is performed at the Company’s CLIA-certified laboratory in San Diego, California. Blood samples are collected and shipped overnight to Prometheus, after which test results are generally reported back to physicians within two to three days.